Calls for Pharmac to expand access to life-changing diabetes monitoring technology - which could save millions in healthcare costs

Continuous Glucose Monitors - or CGMs - have been funded for Type 1 diabetes since last October.

New data from CGM producer Dexcom finds lifetime use of the devices could prevent up to 70-thousand diabetes-related complications - and save more than 600-million in medical costs.

Diabetes New Zealand Chief Executive Heather Verry says funding should be expanded, as anyone who depends on insulin will benefit from the devices.